PHRI researchers delivered a series of presentations on atrial fibrillation at this year’s EHRA Congress, held March 30 to April 1 in Vienna, Austria.
International Fellow Alexander Benz presented a secondary analysis of the IMPROVE-PVI randomized trial titled “Early recurrence of atrial arrhythmia and healthcare utilization during the 8-week blanking period following catheter ablation of atrial fibrillation.”
The study involved 194 patients and tested colchicine (0.6 mg twice daily) vs. placebo for 10 days following atrial fibrillation ablation. Findings showed that nearly 1 in 3 patients experienced early recurrence of atrial arrhythmia in the first two weeks. Colchicine did not reduce recurrence or healthcare use during this period.
Scientist William McIntyre presented recent findings from the prospective, multinational VISION Cardiac Surgery cohort on “Polygenic risk scores for risk prediction of atrial fibrillation in cardiac surgery patients.”
Senior Scientist Jeff Healey took part in a debate on oral anticoagulation in subclinical atrial fibrillation, adding his perspective as a leading expert in the field.
Associate Senior Scientist Deborah Siegal shared results from a sub study of the ARTESiA trial on the “Incidence and predictors of major bleeding among patients receiving apixaban or aspirin for subclinical atrial fibrillation.”
